Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that its senior management team will participate in the 42nd Annual J.P. Morgan Healthcare Conference for a podium presentation and a question-and-answer breakout session. The live webcast of the presentation can be accessed on the company's website.

NEWTON, Mass., Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 42^nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.

A live webcast of the presentation, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 30 days following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-present-at-42nd-annual-jp-morgan-healthcare-conference-302024595.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What is the date and time of Karyopharm Therapeutics Inc.'s presentation at the 42nd Annual J.P. Morgan Healthcare Conference?

The presentation is scheduled for Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.

Where can I access the live webcast of the presentation?

The live webcast of the presentation, along with accompanying slides, can be accessed under 'Events & Presentations' in the Investor section of the company's website, and will be available for replay for 30 days following the event.